Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus JOBEVNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus JOBEVNE.
ABSTRAL vs JOBEVNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
JOBEVNE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine receptor, reducing inflammatory signaling.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
100 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing in most patients
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic